| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
|
Pietrantonio, F.
|
|
|
25 |
2 |
p. 404-408
|
artikel
|
| 2 |
Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?
|
Bergmann, L.
|
|
|
25 |
2 |
p. 303-306
|
artikel
|
| 3 |
Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study
|
Paccou, J.
|
|
|
25 |
2 |
p. 481-486
|
artikel
|
| 4 |
A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor
|
Ravi, P.
|
|
|
25 |
2 |
p. 331-338
|
artikel
|
| 5 |
Antibody-based immunotherapy for ovarian cancer: where are we at?
|
Tse, B.W.C.
|
|
|
25 |
2 |
p. 322-331
|
artikel
|
| 6 |
An update on a systematic review of the use of geriatric assessment for older adults in oncology
|
Puts, M.T.E.
|
|
|
25 |
2 |
p. 307-315
|
artikel
|
| 7 |
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
|
Besse, B.
|
|
|
25 |
2 |
p. 505-511
|
artikel
|
| 8 |
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma †
|
Shinohara, N.
|
|
|
25 |
2 |
p. 472-476
|
artikel
|
| 9 |
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma
|
Ponzoni, M.
|
|
|
25 |
2 |
p. 316-322
|
artikel
|
| 10 |
Body mass index and breast cancer risk in Japan: a pooled analysis of eight population-based cohort studies
|
Wada, K.
|
|
|
25 |
2 |
p. 519-524
|
artikel
|
| 11 |
Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer
|
Hemminki, K.
|
|
|
25 |
2 |
p. 511-518
|
artikel
|
| 12 |
Can tumor location predict effectiveness of bevacizumab conducted in the first-line setting for metastatic colorectal cancer
|
You, K.Y.
|
|
|
25 |
2 |
p. 545-546
|
artikel
|
| 13 |
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
|
Valle, J.W.
|
|
|
25 |
2 |
p. 391-398
|
artikel
|
| 14 |
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
|
Ou, S.-H. I.
|
|
|
25 |
2 |
p. 415-422
|
artikel
|
| 15 |
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy
|
Hadji, P.
|
|
|
25 |
2 |
p. 372-377
|
artikel
|
| 16 |
Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease
|
Atsuta, Y.
|
|
|
25 |
2 |
p. 435-441
|
artikel
|
| 17 |
Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients
|
Cho, J.
|
|
|
25 |
2 |
p. 346-351
|
artikel
|
| 18 |
Do we have a new standard in suboptimal debulked disease?
|
|
|
|
25 |
2 |
p. 547
|
artikel
|
| 19 |
Editorial board
|
|
|
|
25 |
2 |
p. ii-iii
|
artikel
|
| 20 |
Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials
|
Li, X.
|
|
|
25 |
2 |
p. 455-461
|
artikel
|
| 21 |
Efficacy of short-term psychodynamic psychotherapy (STPP) with depressed breast cancer patients: results of a randomized controlled multicenter trial
|
Beutel, M.E.
|
|
|
25 |
2 |
p. 378-384
|
artikel
|
| 22 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
|
Steger, G.G.
|
|
|
25 |
2 |
p. 366-371
|
artikel
|
| 23 |
Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy
|
Streckmann, F.
|
|
|
25 |
2 |
p. 493-499
|
artikel
|
| 24 |
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival
|
Bertucci, F.
|
|
|
25 |
2 |
p. 358-365
|
artikel
|
| 25 |
Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer
|
Orlandi, R.
|
|
|
25 |
2 |
p. 352-357
|
artikel
|
| 26 |
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial †
|
Sternberg, C.N.
|
|
|
25 |
2 |
p. 429-434
|
artikel
|
| 27 |
Is oral chemotherapy prescription safe for patients? A cross-sectional survey
|
Bourmaud, A.
|
|
|
25 |
2 |
p. 500-504
|
artikel
|
| 28 |
Ki67 in breast cancer: a useful prognostic marker?
|
Caldarella, A.
|
|
|
25 |
2 |
p. 542
|
artikel
|
| 29 |
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes
|
Masuda, H.
|
|
|
25 |
2 |
p. 384-391
|
artikel
|
| 30 |
Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer
|
Kawada, T.
|
|
|
25 |
2 |
p. 543
|
artikel
|
| 31 |
Not only chemotherapy in the second-line treatment of metastatic gastric cancer
|
Vasile, E.
|
|
|
25 |
2 |
p. 544-545
|
artikel
|
| 32 |
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
|
Custodio, A.
|
|
|
25 |
2 |
p. 398-403
|
artikel
|
| 33 |
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
|
Kubota, K.
|
|
|
25 |
2 |
p. 529-536
|
artikel
|
| 34 |
Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer
|
Besse, B.
|
|
|
25 |
2 |
p. 409-415
|
artikel
|
| 35 |
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
|
Yu, H.A.
|
|
|
25 |
2 |
p. 423-428
|
artikel
|
| 36 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|
Gnant, M.
|
|
|
25 |
2 |
p. 339-345
|
artikel
|
| 37 |
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes †
|
Efficace, F.
|
|
|
25 |
2 |
p. 447-454
|
artikel
|
| 38 |
Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial
|
Bossi, P.
|
|
|
25 |
2 |
p. 462-466
|
artikel
|
| 39 |
Quality of reporting of phase II trials: a focus on highly ranked oncology journals
|
Grellety, T.
|
|
|
25 |
2 |
p. 536-541
|
artikel
|
| 40 |
Reply to Ki67 in breast cancer: a useful prognostic marker!
|
Denkert, C.
|
|
|
25 |
2 |
p. 542-543
|
artikel
|
| 41 |
Reply to ‘Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer’ by T. Kawada
|
Park, H.
|
|
|
25 |
2 |
p. 543-544
|
artikel
|
| 42 |
Stepping from traditional to integrative medicine: perspectives of Israeli-Arab patients on complementary medicine's role in cancer care
|
Ben-Arye, E.
|
|
|
25 |
2 |
p. 476-480
|
artikel
|
| 43 |
Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival
|
de Vin, T.
|
|
|
25 |
2 |
p. 467-471
|
artikel
|
| 44 |
Table of Contents
|
|
|
|
25 |
2 |
p. iv-vi
|
artikel
|
| 45 |
The landscape of medical oncology in Europe by 2020 †
|
de Azambuja, E.
|
|
|
25 |
2 |
p. 525-528
|
artikel
|
| 46 |
The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients
|
Bozzetti, F.
|
|
|
25 |
2 |
p. 487-493
|
artikel
|
| 47 |
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)
|
Luminari, S.
|
|
|
25 |
2 |
p. 442-447
|
artikel
|
| 48 |
What are the indications for postchemotherapy retroperitoneal lymph node dissection?
|
Einhorn, L.H.
|
|
|
25 |
2 |
p. 301-303
|
artikel
|
Tijdschrift beschrijving